Metabolism elucidation of BJ-B11 (a heat shock protein 90 inhibitor) by human liver microsomes: identification of main contributing enzymes

Bibliography

• Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711–15
   PubMed Web of Science ®Google Scholar
• Lin J, Sahakian DC, de Morais SM, et al. The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr Top Med Chem 2003;3:1125–54
   PubMed Web of Science ®Google Scholar
• Ruiz-Garcia A, Bermejo M, Moss A, Casabo VG. Pharmacokinetics in drug discovery. J Pharm Sci 2008;97:654–90
   PubMed Web of Science ®Google Scholar
• Sheweita SA. Drug-metabolizing enzymes: mechanisms and functions. Curr Drug Metab 2000;1:107–32
   PubMed Web of Science ®Google Scholar
• Alavijeh MS, Palmer AM. The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines. IDrugs 2004;7:755–63
   PubMed Web of Science ®Google Scholar
• Kumar GN, Surapaneni S. Role of drug metabolism in drug discovery and development. Med Res Rev 2001;21:397–411
   PubMed Web of Science ®Google Scholar
• Yengi LG, Leung L, Kao J. The evolving role of drug metabolism in drug discovery and development. Pharm Res 2007;24:842–58
   PubMed Web of Science ®Google Scholar
• Rowland A, Miners JO, Mackenzie PI. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol 2013;45:1121–32
   PubMed Web of Science ®Google Scholar
• Testa B, Pedretti A, Vistoli G. Reactions and enzymes in the metabolism of drugs and other xenobiotics. Drug Discov Today 2012;17:549–60
   PubMed Web of Science ®Google Scholar
• Ong CE, Pan Y, Mak JW, Ismail R. In vitro approaches to investigate cytochrome P450 activities: update on current status and their applicability. Expert Opin Drug Metab Toxicol 2013;9:1097–113
   PubMed Web of Science ®Google Scholar
• Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002;34:83–448
   PubMed Web of Science ®Google Scholar
• Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002;360:1155–62
   PubMed Web of Science ®Google Scholar
• Lewis DF. 57 varieties: the human cytochromes P450. Pharmacogenomics 2004;5:305–18
   PubMed Web of Science ®Google Scholar
• Anzenbacher P, Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 2001;58:737–47
   PubMed Web of Science ®Google Scholar
• Fukami T, Yokoi T. The emerging role of human esterases. Drug Metab Pharmacokinet 2012;27:466–77
   PubMed Web of Science ®Google Scholar
• Imai T, Taketani M, Shii M, et al. Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab Dispos 2006;34:1734–41
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Fukami T, Nakajima A, et al. Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse. Drug Metab Dispos 2012;40:671–9
   PubMed Web of Science ®Google Scholar
• Ross MK, Crow JA. Human carboxylesterases and their role in xenobiotic and endobiotic metabolism. J Biochem Mol Toxicol 2007;21:187–96
   PubMed Web of Science ®Google Scholar
• Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov Today 2008;13:38–43
   PubMed Web of Science ®Google Scholar
• Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 2006;75:271–94
   PubMed Web of Science ®Google Scholar
• Neckers L, Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update. Expert Opin Emerg Drugs 2005;10:137–49
   PubMedGoogle Scholar
• Li Y, Zhang T, Schwartz SJ, Sun D. New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat 2009;12:17–27
   PubMed Web of Science ®Google Scholar
• Barta TE, Veal JM, Rice JW, et al. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90. Bioorg Med Chem Lett 2008;18:3517–21
   PubMed Web of Science ®Google Scholar
• Huang KH, Veal JM, Fadden RP, et al. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem 2009;52:4288–305
   PubMed Web of Science ®Google Scholar
• Kim T, Keum G, Pae AN. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives. Expert Opin Ther Pat 2013;23:919–43
   PubMed Web of Science ®Google Scholar
• Bhat R, Tummalapalli SR, Rotella DP. Progress in the discovery and development of heat shock protein 90 (hsp90) inhibitors. J Med Chem 2014;57:8718–28
   PubMed Web of Science ®Google Scholar
• Ju HQ, Xiang YF, Xin BJ, et al. Synthesis and in vitro anti-HSV-1 activity of a novel Hsp90 inhibitor BJ-B11. Bioorg Med Chem Lett 2011;21:1675–7
   PubMed Web of Science ®Google Scholar
• Ju HQ, Wang SX, Xiang YF, et al. BJ-B11, a novel Hsp90 inhibitor, induces apoptosis in human chronic myeloid leukemia K562 cells through the mitochondria-dependent pathway. Eur J Pharmacol 2011;666:26–34
   PubMed Web of Science ®Google Scholar
• Liu KS, Zhang Y, Ding WC, et al. The selective Hsp90 inhibitor BJ-B11 exhibits potent antitumor activity via induction of cell cycle arrest, apoptosis and autophagy in Eca-109 human esophageal squamous carcinoma cells. Int J Oncol 2012;41:2276–84
   PubMed Web of Science ®Google Scholar
• Fang ZZ, Krausz KW, Nagaoka K, et al. In vivo effects of the pure aryl hydrocarbon receptor antagonist GNF-351 after oral administration are limited to the gastrointestinal tract. Br J Pharmacol 2014;171:1735–46
   PubMed Web of Science ®Google Scholar
• Liu W, Liu H, Sun H, et al. Metabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS). Xenobiotica 2014;44:455–64
   PubMed Web of Science ®Google Scholar
• Bateman KP, Castro-Perez J, Wrona M, et al. MSE with mass defect filtering for in vitro and in vivo metabolite identification. Rapid Commun Mass Spectrom 2007;21:1485–96
   PubMed Web of Science ®Google Scholar
• Shimizu M, Fukami T, Nakajima M, Yokoi T. Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase. Drug Metab Dispos 2014;42:1103–9
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Fukami T, Shimizu M, et al. Contributions of arylacetamide deacetylase and carboxylesterase 2 to flutamide hydrolysis in human liver. Drug Metab Dispos 2012;40:1080–4
   PubMed Web of Science ®Google Scholar
• Shimizu M, Fukami T, Ito Y, et al. Indiplon is hydrolyzed by arylacetamide deacetylase in human liver. Drug Metab Dispos 2014;42:751–8
   PubMed Web of Science ®Google Scholar
• Watanabe A, Fukami T, Takahashi S, et al. Arylacetamide deacetylase is a determinant enzyme for the difference in hydrolase activities of phenacetin and acetaminophen. Drug Metab Dispos 2010;38:1532–7
   PubMed Web of Science ®Google Scholar
• Takahashi S, Katoh M, Saitoh T, et al. Different inhibitory effects in rat and human carboxylesterases. Drug Metab Dispos 2009;37:956–61
   PubMed Web of Science ®Google Scholar
• Hosokawa M, Endo T, Fujisawa M, et al. Interindividual variation in carboxylesterase levels in human liver microsomes. Drug Metab Dispos 1995;23:1022–7
   PubMed Web of Science ®Google Scholar
• Watanabe A, Fukami T, Nakajima M, et al. Human arylacetamide deacetylase is a principal enzyme in flutamide hydrolysis. Drug Metab Dispos 2009;37:1513–20
   PubMed Web of Science ®Google Scholar
• Nakajima A, Fukami T, Kobayashi Y, et al. Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. Biochem Pharmacol 2011;82:1747–56
   PubMed Web of Science ®Google Scholar
• Gonzalvo MC, Gil F, Hernandez AF, et al. Human liver paraoxonase (PON1): subcellular distribution and characterization. J Biochem Mol Toxicol 1998;12:61–9
   PubMed Web of Science ®Google Scholar
• Jbilo O, Bartels CF, Chatonnet A, et al. Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA. Toxicon 1994;32:1445–57
   PubMed Web of Science ®Google Scholar
• Takusagawa S, Yajima K, Miyashita A, et al. Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective beta3-adrenoceptor agonist. Xenobiotica 2012;42:957–67
   PubMed Web of Science ®Google Scholar
• Preuss CV, Svensson CK. Arylacetamide deacetylase activity towards monoacetyldapsone. Species comparison, factors that influence activity, and comparison with 2-acetylaminofluorene and p-nitrophenyl acetate hydrolysis. Biochem Pharmacol 1996;51:1661–8
   PubMed Web of Science ®Google Scholar